HTLV-I-Associated Myelopathy Clinical Trial
Official title:
Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
An open-label, non-randomised, uncontrolled, proof-of-concept study of patients with HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Participants will receive oral administration of tamibarotene in the amount of 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks. The patients will be followed up for further 8 weeks. Efficacy will be monitored by measuring clinical scores including motor and urination function, HTLV-1 proviral load, immunological parameters, and markers in the spinal fluid. Safety will be evaluated at the same time.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00823641 -
The HAM Infliximab Study
|
Phase 2 | |
Completed |
NCT00272480 -
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT00519181 -
Safety and Efficiency Study of Valproic Acid In HAM/TSP
|
N/A |